These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 22031859)

  • 1. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
    Benson DM; Bakan CE; Zhang S; Collins SM; Liang J; Srivastava S; Hofmeister CC; Efebera Y; Andre P; Romagne F; Bléry M; Bonnafous C; Zhang J; Clever D; Caligiuri MA; Farag SS
    Blood; 2011 Dec; 118(24):6387-91. PubMed ID: 22031859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.
    Romagné F; André P; Spee P; Zahn S; Anfossi N; Gauthier L; Capanni M; Ruggeri L; Benson DM; Blaser BW; Della Chiesa M; Moretta A; Vivier E; Caligiuri MA; Velardi A; Wagtmann N
    Blood; 2009 Sep; 114(13):2667-77. PubMed ID: 19553639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.
    Benson DM; Cohen AD; Jagannath S; Munshi NC; Spitzer G; Hofmeister CC; Efebera YA; Andre P; Zerbib R; Caligiuri MA
    Clin Cancer Res; 2015 Sep; 21(18):4055-61. PubMed ID: 25999435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma.
    Carlsten M; Korde N; Kotecha R; Reger R; Bor S; Kazandjian D; Landgren O; Childs RW
    Clin Cancer Res; 2016 Nov; 22(21):5211-5222. PubMed ID: 27307594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.
    Benson DM; Hofmeister CC; Padmanabhan S; Suvannasankha A; Jagannath S; Abonour R; Bakan C; Andre P; Efebera Y; Tiollier J; Caligiuri MA; Farag SS
    Blood; 2012 Nov; 120(22):4324-33. PubMed ID: 23033266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
    Benson DM; Bakan CE; Mishra A; Hofmeister CC; Efebera Y; Becknell B; Baiocchi RA; Zhang J; Yu J; Smith MK; Greenfield CN; Porcu P; Devine SM; Rotem-Yehudar R; Lozanski G; Byrd JC; Caligiuri MA
    Blood; 2010 Sep; 116(13):2286-94. PubMed ID: 20460501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
    Wu L; Parton A; Lu L; Adams M; Schafer P; Bartlett JB
    Cancer Immunol Immunother; 2011 Jan; 60(1):61-73. PubMed ID: 20848094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission.
    Vey N; Bourhis JH; Boissel N; Bordessoule D; Prebet T; Charbonnier A; Etienne A; Andre P; Romagne F; Benson D; Dombret H; Olive D
    Blood; 2012 Nov; 120(22):4317-23. PubMed ID: 23002117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide down regulates the production of interferon-gamma and the expression of inhibitory cytotoxic receptors of human Natural Killer cells.
    Dauguet N; Fournié JJ; Poupot R; Poupot M
    Cell Immunol; 2010; 264(2):163-70. PubMed ID: 20621290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
    Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
    Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.
    Nijhof IS; Lammerts van Bueren JJ; van Kessel B; Andre P; Morel Y; Lokhorst HM; van de Donk NW; Parren PW; Mutis T
    Haematologica; 2015 Feb; 100(2):263-8. PubMed ID: 25510242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers.
    Alici E
    Curr Opin Mol Ther; 2010 Dec; 12(6):724-33. PubMed ID: 21154164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
    Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
    Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
    Tai YT; Li XF; Catley L; Coffey R; Breitkreutz I; Bae J; Song W; Podar K; Hideshima T; Chauhan D; Schlossman R; Richardson P; Treon SP; Grewal IS; Munshi NC; Anderson KC
    Cancer Res; 2005 Dec; 65(24):11712-20. PubMed ID: 16357183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.
    Korde N; Carlsten M; Lee MJ; Minter A; Tan E; Kwok M; Manasanch E; Bhutani M; Tageja N; Roschewski M; Zingone A; Costello R; Mulquin M; Zuchlinski D; Maric I; Calvo KR; Braylan R; Tembhare P; Yuan C; Stetler-Stevenson M; Trepel J; Childs R; Landgren O
    Haematologica; 2014 Jun; 99(6):e81-3. PubMed ID: 24658821
    [No Abstract]   [Full Text] [Related]  

  • 16. Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands.
    Chan WK; Kung Sutherland M; Li Y; Zalevsky J; Schell S; Leung W
    Clin Cancer Res; 2012 Nov; 18(22):6296-305. PubMed ID: 23014531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.
    Balasa B; Yun R; Belmar NA; Fox M; Chao DT; Robbins MD; Starling GC; Rice AG
    Cancer Immunol Immunother; 2015 Jan; 64(1):61-73. PubMed ID: 25287778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.
    Besson L; Charrier E; Karlin L; Allatif O; Marçais A; Rouzaire P; Belmont L; Attal M; Lombard C; Salles G; Walzer T; Viel S
    Front Immunol; 2018; 9():704. PubMed ID: 29706958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
    Igarashi T; Wynberg J; Srinivasan R; Becknell B; McCoy JP; Takahashi Y; Suffredini DA; Linehan WM; Caligiuri MA; Childs RW
    Blood; 2004 Jul; 104(1):170-7. PubMed ID: 15016654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.
    Tai YT; Horton HM; Kong SY; Pong E; Chen H; Cemerski S; Bernett MJ; Nguyen DH; Karki S; Chu SY; Lazar GA; Munshi NC; Desjarlais JR; Anderson KC; Muchhal US
    Blood; 2012 Mar; 119(9):2074-82. PubMed ID: 22246035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.